Welcome to our dedicated page for Surmodics news (Ticker: SRDX), a resource for investors and traders seeking the latest updates and insights on Surmodics stock.
Surmodics Inc. (SRDX) drives innovation in medical device coatings and diagnostic solutions through partnerships with global healthcare leaders. This news center delivers verified updates on the company's financial developments, regulatory milestones, and technological breakthroughs shaping patient care.
Find curated press releases detailing SRDX's advancements in vascular intervention systems, diagnostic platform enhancements, and strategic collaborations. Track earnings reports and product launch announcements that highlight the company's transition from coating pioneer to comprehensive medical solution developer.
Our repository includes updates on FDA clearances, clinical study results, and manufacturing expansions critical for assessing SRDX's market position. Discover how the company's surface modification expertise addresses challenges in drug delivery systems and in-vitro diagnostics.
Bookmark this page for ongoing insights into Surmodics' role in medical innovation. Return regularly to stay informed about developments impacting the future of minimally invasive therapies and diagnostic accuracy.
Surmodics, Inc. (Nasdaq: SRDX) reported Q2 fiscal 2023 financial results showing total revenue of $27.2 million, a 4% increase year-over-year. However, the company reported a GAAP diluted earnings per share (EPS) loss of $(0.55) compared to $(0.29) in the same period last year. Non-GAAP EPS also declined to $(0.40) from $(0.22).
Key highlights include a 7% increase in Medical Device revenue to $19.7 million, driven by strong sales of the Pounce and Sublime platforms. Despite this growth, the company faced challenges with FDA approval for its SurVeil drug-coated balloon, which remains under review. Surmodics updated its fiscal year 2023 revenue guidance to between $103 million and $106 million, indicating an increase of 3% to 6% compared to the previous year.
Surmodics, Inc. (Nasdaq: SRDX) announces the enrollment of the first patient in the PROWL registry for the Pounce™ Thrombectomy System. This open-label, multi-center registry aims to collect real-world outcomes data for non-surgical emboli removal in up to 500 patients at 30 sites across the U.S. The primary endpoints include procedural success and device-related major adverse events over 30 days. National Co-Principal Investigators are Dr. Sean Lyden (Cleveland Clinic) and Dr. Joseph Campbell (OhioHealth). The PROWL study addresses the urgent medical need for effective treatment of acute limb ischemia, which poses significant risks of amputation and mortality. The Pounce system efficiently removes clots, potentially reducing the need for expensive adjunctive treatments in hospital settings.
Surmodics, Inc. (Nasdaq: SRDX) will announce its second quarter fiscal 2023 financial results before the market opens on April 26, 2023.
A live webcast and conference call will be conducted at 7:00 a.m. CT on the same day to discuss these results and accomplishments, including a Q&A session. The event can be accessed through the company’s website under “Events & Presentations.” An audio replay will be available from 11:00 a.m. CT on April 26 until 11:00 a.m. CT on May 10.
Surmodics specializes in performance coating technologies for medical devices and in vitro diagnostics and aims to enhance disease detection and treatment.
FAQ
What is the current stock price of Surmodics (SRDX)?
What is the market cap of Surmodics (SRDX)?
